New developments in cancer treatment with the novel thymidylate synthase inhibitor raltitrexed ('Tomudex')

British Journal of Cancer

Volumn 77, Issue SUPPL. 2, 1998, Pages 29-37

  Blackledge, G ^a  

^a ASTRAZENECA   (United Kingdom)

Author keywords

Additivity; Combination therapy; Monotherapy; Raltitrexed; Synergism

Indexed keywords

ANTHRACYCLINE; CISPLATIN; CYTOTOXIC AGENT; DNA TOPOISOMERASE INHIBITOR; DOCETAXEL; DOXORUBICIN; FLUOROURACIL; IRINOTECAN; OXALIPLATIN; PACLITAXEL; PLATINUM DERIVATIVE; RALTITREXED; TAXANE DERIVATIVE; THYMIDYLATE SYNTHASE INHIBITOR;

ADVANCED CANCER; ASTHENIA; BONE MARROW SUPPRESSION; CARDIOTOXICITY; CHILDHOOD CANCER; CLINICAL TRIAL; COLORECTAL CANCER; CONFERENCE PAPER; CONGESTIVE CARDIOMYOPATHY; DIARRHEA; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG TOLERABILITY; FLUID RETENTION; GASTROINTESTINAL TOXICITY; HEAD AND NECK CANCER; HEART ARRHYTHMIA; HUMAN; LEUKEMIA; MUCOSA INFLAMMATION; NAUSEA; NEPHROTOXICITY; NEUTROPENIA; PERIPHERAL NEUROPATHY; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROSTATE CANCER; QUALITY OF LIFE; SKIN TOXICITY; SOFT TISSUE SARCOMA; SOLID TUMOR; STOMACH CARCINOMA; VOMITING;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CLINICAL TRIALS, PHASE I; COLORECTAL NEOPLASMS; COMBINED MODALITY THERAPY; ENZYME INHIBITORS; HUMANS; QUINAZOLINES; THIOPHENES; THYMIDYLATE SYNTHASE;

EID: 0031887874     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1038/bjc.1998.423     Document Type: Article

References (46)

1. Ackland S, Kuiper CM, Garg M, Bergman AM, Smid K and Peters GJ (1996) Variable effects of the combination of Tomudex (ZD1694) and cisplatin in ovarian cancer cell lines (abstract). Ann Oncol 7: 7
2. Allen-Mersh TG, Earlam S, Fordy C, Abrams K and Houghton J (1994) Quality of life and survival with continuous hepatic-artery floxuridine infusion for colorectal liver metastases. Lancet 344: 1255-1260
3. Armand J, Ducreux M, Mahjoubi M, Abigerges D, Bugat R, Chabot G, Herait P, de Forni M and Rougier P (1995) CPT 11 (Irinotecan) in the treatment of colorectal cancer. Eur J Cancer 31A: 1283-1287
4. Aschele C, Baldo C, Guglielmi A and Sobrero A (1995) In vitro synergism between Tomudex and SN-38 in human colon cancer cells (abstract 400). Tumori 81 (suppl.): 132
5. Aschele C, Baldo C, Guglielmi A, Sobrero A and Bertino JR (1996a) Sequence dependent synergism between Tomudex and Irinolecan in human cancer cells in vitro (abstract 302). Ann Oncol 7 (suppl. 1): 88
6. Aschele C, Sobrero A, Baldo C, Ardizzoni A, Bommann WG and Bertino JR (1996b) In vitro synergism between SN-38 and Tomudex (TX): importance of scheduling and dose ratio (abstract 621P). Ann Oncol 7(suppl. 5): 129
7. Chang YM, Zielinski Z and Izzo J (1994) Pretreatment of colon carcinoma cells to D1696 (Tomudex) markedly enhances 5-fluorouracil toxicity (abstract). Proc Am Assoc Cancer Res 35: A1966
8. Cunningham D, Zalcberg JR, Rath U, Oliver I, van Cutsem E, Svensson C, Seitz JF, Harper P, Kerr D, Perez-Manga G and the Tomudex Colorectal Cancer Study Group (1996a) Final results of a randomised trial comparing 'Tomudex'® (raltitrexed) with 5-fluorouracil plus leucovorin in advanced colorectal cancer. Ann Oncol 7: 961-965
9. Cunningham D, Zalcberg J, Smith I, Gore M, Pazdur R, Burris H IIIrd, Meropol NJ, Kennealey G and Seymour L (1996b) 'Tomudex' (ZD1694): a novel thymidylate synthase inhibitor with clinical antitumour activity in a range of solid tumours. Ann Oncol 7: 179-182
10. de Gramont A, Gastiaburu J, Tournigand C, Louvet C, Varette C, Raymond E, Lecouturier S, Brienza S and Krulik M (1994) Oxaliplatin with high-dose folinic acid and 5-fluorouracil 48 h infusion in pretreated metastatic colorectal cancer (abstract). Proc Am Soc Clin Oncol 13: 220
11. Harper P (1997) Advanced colorectal cancer (ACC): results from the latest (raltitrexed) Tomudex comparative study (abstract 802). Proc Am Soc Clin Oncol 16: 228a
12. Harstrick A, Schleucher N, Gonzales A, Schmidt C, Hoffmann A, Wilke H, Rustum Y and Seeber S (1995) Interactions and cross resistance patterns between various schedules of 5-FU and the new, folate-based thymidylate synthase inhibitor 'Tomudex' (D1694). Eur J Cancer 31A(suppl. 5): S30
13. Horwitz SB (1994) Taxol (paclitaxel): mechanisms of action. Ann Oncol 5: S3-S6
14. Izzo J, Zielinski Z, Chang YM and Bertino JR (1995) Molecular mechanisms of the synergistic sequential administration of D1694 (Tomudex) followed by FUra in colon carcinoma cells (abstract). Proc Am Assoc Cancer Res 36: 381
15. Jackman AL and Gibson W (1995) Polyglutamation of the thymidylate synthase inhibitor, ZD 1694 (Tomudex) in normal mouse tissues (abstract). Proc Am Assoc Cancer Res, 36: 377
16. Jackman AL and Judson IR (1996) The new generation of thymidylate synthase inhibitors in clinical study. Exp Opin Invest Drugs 5: 719-736
17. Jackman AL, Taylor GA, Gibson W, Kimbell R, Brown M, Calvert AH, Judson IR and Hughes LR (1991) ICI D1694, a quinazoline antifolate thymidylate synthase inhibitor that is a potent inhibitor of L1210 tumor cell growth in vitro and in vivo: a new agent for clinical study. Cancer Res 51: 5579-5586
18. Jackman AL, Farrugia DC, Gibson W, Kimbell R, Harrap KR, Stephens TC, Azab M and Boyle FT (1995) ZD1694 (Tomudex): a new thymidylate synthase inhibitor with activity in colorectal cancer. Eur J Cancer 31A: 1277-1282
19. Kelland LR, Kimbell R, Hardcastle A, Aherne GW and Jackman AL (1995) Relationships between resistance to cisplatin and antifolates in sensitive and resistant tumour cell lines. Eur J Cancer 31A: 981-986
20. Kerr DJ (1997) Clinical efficacy of 'Tomudex' (raltitrexed) in advanced colorectal cancer. Anticancer Drugs 8 (suppl. 2): S11-S15
21. Kimbell R, Brunton L and Jackman AL (1996) Combination studies with Tomudex and 5-fluorouracil in human colon cancer cell lines (abstract). Br J Cancer 73: 29
22. Levi FA, Misset JL, Brienza S, Adam R, Metzger G, Itzakhi M, Caussanel JP, Kunstlinger F, Lecouturier S and Descorps-Declére A (1992) A chronopharmacologic phase II clinical trial with 5-fluorouracil, folinic acid and oxaliplatin using an ambulatory multichannel programmable pump. Cancer 69: 893-900
23. Levi FA, Zidani R, Vannetzel J-M, Perpoint B, Focan C, Faggiuolo R, Chollet P, Garufi C, Itzhaki M and Dogliotti L (1994) Chronomodulated versus fixed-infusion-rate delivery of ambulatory chemotherapy with oxaliplatin, fluorouracil, and folinic acid (leucovorin) in patients with colorectal cancer metastases: a randomized multi-institutional trial. J Natl Cancer Inst 86: 1608-1617
24. Levi FA, Giacchetti S, Adam R, Zidani R, Metzger G and Misset JL (1995) Chronomodulation of chemotherapy against metastatic colorectal cancer. Eur J Cancer 31A: 1264-1270
25. Mayer RJ, O'Connell MJ, Tepper JE and Wolmark N (1989) Status of adjuvant therapy for colorectal cancer. J Natl Cancer Inst 81: 1359-1364
26. McKeage MJ (1995) Comparative adverse effect profiles of platinum drugs. Drug Safety 13: 228-244
27. Moertel CG (1994) Chemotherapy for colorectal cancer. N Engl J Med 330: 1136-1142
28. Nordic Gastrointestinal Tumour Adjuvant Therapy Group (1992) Expectancy or primary chemotherapy in patients with advanced asymptomatic colorectal cancer. J Clin Oncol 10: 904-911
29. Pazdur R and Vincent M (1997) Raltitrexed (Tomudex) vs 5-fluorouracil + leucovorin (5-FU + LV) in patients with advanced colorectal cancer (ACC): results of a randomised multicenter North American trial (abstract). Proc Am Soc Clin Oncol 16: 228a
30. Ratain MJ (1997) Pharmacology of cancer chemotherapy. In Cancer: Principles and Practice of Oncology, De Vita Jr VT, Hellman S and Rosenberg SA. (eds), pp. 375-512. Lippincott-Raven: Philadelphia, PA
31. Raymond E, Djelloul S, Buquet Fagot C, Goldwasser F, Mester J, Cvitkovic E, Louvet C and Gespach C (1996) Oxaliplatin (LOHP) and cisplatin (CDDP) in combination with 5FU, specific thymidylate synthase (TS) inhibitors (AG337, ZD1694), and topoisomerase I (Topo-I) inhibitors (SN38, CPT-11) in human colonic, ovarian and breast cancers (abstract). Proc Am Assoc Cancer Res 37: 291
32. Rougier PU and Bugat R (1996) CPT-11 in the treatment of a colorectal cancer: clinical efficacy and safety profile. Semin Oncol 23: 34-41
33. Rougier PH, Ducreux M, Kerr D, Carr BI, François E, Adenis A and Seymour A (1997) A phase II study of raltitrexed ('Tomudex') in patients with hepatocellular carcinoma. Ann Oncol 8: 500-502
34. Rowinsky EK and Donehower RC (1995) Drug therapy: paclitaxel (Taxol). N Engl J Med 332: 1004-1014
35. Rowinsky EK, Cazenave LA and Donehower RC (1990) Taxol: a novel investigational antineoplastic agent. J Natl Cancer Inst 82: 1247
36. Rustum YM, Harstrick A, Cao S, Vanhoefer U, Yin M-B, Wilke H and Weeber S (1997) Thymidylate synthase inhibitors in cancer therapy: direct and indirect inhibitors. J Clin Oncol 15: 389-400
37. Scheithauer W, Rosen U, Kornek G-V, Sebesta C and Depisch D (1993) Randomised comparison of combination chemotherapy plus supportive care with supportive care alone in patients with metastatic colorectal cancer. Br Med J 306: 752-755
38. Schiff PB and Horwitz SB (1980) Taxol stabilizes microtubules in mouse fibroblast cells. Proc Natl Acad Sci USA 77: 1561-1565
39. Schwartz GK, Kemeny N, Saltz L, Sugarman A, Danso D, Kelsen DK, Tong W and Bertino J (1997) Phase I trial of sequential Tomudex® (TOM) and 5-fluorouracil (5-FU) in patients with advanced colorectal cancer (abstract 728). Proc Am Soc Clin Oncol 16: 208a
40. Seidman AD (1995) The emerging role of paclitaxel in breast cancer therapy. Clin Cancer Res 1: 247
41. Sobrero AF, Aschele C and Bertino JR (1997) Fluorouracil in colorectal cancer - a tale of two drugs: implications for biochemical modulation. J Clin Oncol 15: 368-381
42. Teicher BA and Coleman CN (1997) Enhanced radiation response by 'Tomudex' in vitro and in vivo (abstract). Proc Am Assoc Cancer Res 38: 537-538
43. Touroutoglou N and Pazdur R (1996) Thymidylate synthase inhibitors. Clin Cancer Res 2: 227-243
44. Van Cutsem E, Cunningham D, Ten Bokkel Huinink W, Dirix L, Punt C, Alexopoulos C, Cote C, Blanc C and Bleiberg H (1996) Irinotecan (CPT-11) multicenter phase II study in colorectal cancer patients with documented progressive disease on prior 5FU: preliminary results. Proc Am Soc Clin Oncol 15: 562
45. Verweij J and Schellens J (1995) Topoisomerase I inhibition: a new target or new missiles? Ann Oncol 6: 102-104
46. Zalcberg JR (1997) Overview of the tolerability of 'Tomudex' (raltitrexed): collective clinical experience in advanced colorectal cancer. Anticancer Drugs 8: S17-S22